Is OMEROS CORP (OMER) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 25.3% / 30% | 11.0% / 30% | 4.5% / 30% | N/A | ✓ HALAL |
| DJIM | 25.3% / 33% | 11.0% / 33% | 4.5% / 33% | N/A | ✓ HALAL |
| MSCI | 74.7% / 33% | 32.5% / 33% | 13.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 25.3% / 33% | 11.0% / 33% | 4.5% / 33% | N/A | ✓ HALAL |
| FTSE | 74.7% / 33% | 32.5% / 33% | 13.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -32.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$149M |
| Free Cash Flow | -$149M |
| Total Debt | $207M |
| Current Ratio | 0.9 |
| Total Assets | $277M |
Price & Trading
| Last Close | $10.30 |
| 50-Day MA | $11.49 |
| 200-Day MA | $7.73 |
| Avg Volume | 2.2M |
| Beta | 2.5 |
|
52-Week Range
$2.95
| |
About OMEROS CORP (OMER)
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is OMEROS CORP (OMER) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), OMEROS CORP is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is OMEROS CORP's debt ratio?
OMEROS CORP's debt ratio is 25.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 74.7%.
What are OMEROS CORP's key financial metrics?
OMEROS CORP has a market capitalization of $700M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.